The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 201–300 of 999
Doehner, W., Gerstein, H. C., Ried, J. S., Jung, H., Asbrand, C., Hess, S., & Anker, S. D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa293 · Cited by 92
Kohsaka, S., Lam, C. S. P., Kim, D. J., Cavender, M. A., Norhammar, A., Jørgensen, M. E., Birkeland, K. I., Holl, R. W., Franch‐Nadal, J., Tangri, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30130-3 · Cited by 94
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 92
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Dütting, E. D., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 94
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
and the DPP Research Group, Nathan, D. M., Bennett, P. H., Crandall, J. P., Edelstein, S. L., Goldberg, R. B., Kahn, S. E., Knowler, W. C., Mather, K. J., Mudaliar, S., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4928-8 · Cited by 91
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
Hsueh, W., McLellan, K., Wyne, K., & Villagomez, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39564 · Cited by 91
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 97
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Morgan, C. L., Poole, C., Evans, M., Barnett, A. H., Jenkins‐Jones, S., & Currie, C. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3034 · Cited by 90
Erion, D. M., Park, H., & Lee, H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.3.268 · Cited by 89
Farooqi, M. A., Gerstein, H. C., Yusuf, S., & Leong, D. P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014686 · Cited by 93
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 93
Evolution of Insulin: From Human to Analog
Tibaldi, J. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.005 · Cited by 91
Kahn, S. E., Deanfield, J. E., Jeppesen, O. K., Emerson, S. S., Boesgaard, T. W., Colhoun, H. M., Kushner, R. F., Lingvay, I., Burguera, B. G., Gajos, G., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0491 · Cited by 102
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 90
Evidence‐based diabetes care for older people with Type 2 diabetes: a critical review
Sinclair, A. J., Abdelhafiz, A. H., Forbes, A., & Munshi, M. N. (2018) · Diabetic Medicine · doi:10.1111/dme.13859 · Cited by 90
Identifying and meeting the challenges of insulin therapy in type 2 diabetes
SORLI, C. H., & HEILE, M. K. (2014) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s64084 · Cited by 95
Bedenis, R., Price, A. H., Robertson, C. M., Morling, J. R., Frier, B. M., Strachan, M. W. J., & Price, J. F. (2014) · Diabetes Care · doi:10.2337/dc14-0908 · Cited by 87
Zhang, L., Zhang, Y., Shen, S., Wang, X., Dong, L., Li, Q., Ren, W., Li, Y., Bai, J., Gong, Q., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00132-8 · Cited by 92
Bordeleau, L. J., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J. L., Yu, P. C., Rydén, L., Pīrāgs, V., Spinas, G. A., Birkeland, K. I., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1468 · Cited by 86
Matsuhisa, M., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., Hirose, T., & on behalf of the EDITION JP 1 study group (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12619 · Cited by 85
Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska, K. J., & Krumholz, H. M. (2017) · JAMA · doi:10.1001/jama.2017.0029 · Cited by 85
Novel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 88
Strategies for participant retention in long term clinical trials
Poongothai, S., Anjana, R. M., Aarthy, R., Ranjit Unnikrishnan, I., Narayan, K. M. V., Ali, M. K., Karkuzhali, K., & Mohan, V. (2022) · Perspectives in Clinical Research · doi:10.4103/picr.picr_161_21 · Cited by 85
Barriers and solutions to diabetes management: An Indian perspective
Wangnoo, S., Maji, D., Das, A., Rao, P., Moses, A., Sethi, B. K., Unnikrishnan, A., Kalra, S., Balaji, V., Bantwal, G., et al. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113749 · Cited by 85
Rethinking the Relationship between Insulin and Cancer
Vigneri, R., Sciacca, L., & Vigneri, P. G. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.05.004 · Cited by 90
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Booth, G. L., Lipscombe, L. L., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., Simpson, S. H., et al. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.09.003 · Cited by 82
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 81
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Heerspink, H. J. L., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00030-3 · Cited by 83
Inzucchi, S. E., FITCHETT, D. H., Jurišić‐Eržen, D., Woo, V. C., Hantel, S., Janista, C., Kaspers, S., George, J. T., Zinman, B., & on behalf of the EMPA‐REG OUTCOME® Investigators (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13938 · Cited by 82
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 82
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
Hong, K. N., Fuster, V., Rosenson, R. S., Rosendorff, C., & Bhatt, D. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.001 · Cited by 87
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 84
The past, present, and future of basal insulins
Pettus, J., Cavaiola, T. S., Tamborlane, W. V., & Edelman, S. V. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 83
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Pigeyre, M., Hess, S., Gomez, M. F., Asplund, O., Groop, L., Paré, G., & Gerstein, H. (2022) · Diabetologia · doi:10.1007/s00125-021-05567-4 · Cited by 79
Year in Diabetes 2012: The Diabetes Tsunami
Sherwin, R. S., & Jastreboff, A. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3487 · Cited by 82
SGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. M., & Inzucchi, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0943-4 · Cited by 80
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 84
Kunutsor, S. K., Balasubramanian, V. G., Zaccardi, F., Gillies, C., Aroda, V. R., Seidu, S., & Khunti, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15511 · Cited by 94
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 78
Factors associated with weight gain in people with type 2 diabetes starting on insulin
Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc13-3010 · Cited by 77
Al-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 80
Metwally, A. A., Perelman, D., Park, H., Wu, Y., Jha, A., Sharp, S. A., Celli, A., Ayhan, E. M., Abbasi, F., Gloyn, A. L., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01311-6 · Cited by 98
The ORIGIN Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-1329 · Cited by 75
Self-citationShi, W., Sheng, X., Dorr, K. M., Hutton, J. E., Emerson, J. I., Davies, H. A., Andrade, T. D., Wasson, L. K., Greco, T. M., Hashimoto, Y., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.09.022 · Cited by 75
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
Inzucchi, S. E., Viscoli, C. M., Young, L. H., Furie, K. L., Gorman, M., Lovejoy, A. M., Dagogo-Jack, S. E., Ismail‐Beigi, F., Korytkowski, M. T., Pratley, R. E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0798 · Cited by 76
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?
Fagot, J., Blotière, P., Ricordeau, P., Weill, A., Alla, F., & Allemand, H. (2012) · Diabetes Care · doi:10.2337/dc12-0506 · Cited by 74
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 73
Bell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 75
Kong, A. P. S., Yang, X., Luk, A. O. Y., Ronald, C. W., So, W. Y., Ozaki, R., Ting, R. Z. W., Cheung, K. K.-T., Ho, C. S., Chan, M. H. M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2507 · Cited by 73
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Schernthaner, G.-H., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12412 · Cited by 73
Scheen, M., Giraud, R., & Bendjelid, K. (2021) · Physiological Reports · doi:10.14814/phy2.14713 · Cited by 88
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 76
Insulin resistance: a risk marker for disease and disability in the older person
Krentz, A. J., Viljoen, A., & Sinclair, A. J. (2012) · Diabetic Medicine · doi:10.1111/dme.12063 · Cited by 75
Marx, N., McGuire, D. K., Perkovic, V., Woerle, H., Broedl, U. C., von Eynatten, M., George, J. T., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dc17-0068 · Cited by 73
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 71
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 72
Sattar, N., Presslie, C., Rutter, M. K., & McGuire, D. K. (2024) · Diabetes Care · doi:10.2337/dci23-0041 · Cited by 70
Shen, L., Rørth, R., Cosmi, D., Kristensen, S. L., Petrie, M. C., Cosmi, F., Latini, R., Køber, L., Anand, I. S., Carson, P. E., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1535 · Cited by 69
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 74
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 75
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Prattichizzo, F., Sala, L. L., Rydén, L., Marx, N., Ferrini, M., Valensi, P. E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880040 · Cited by 70
The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer
Ferguson, R. D., Gallagher, E. J., Scheinman, E. J., Damouni, R., & LeRoith, D. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00010-1 · Cited by 72
Definition of intervention points in prediabetes
Ferrannini, E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70175-x · Cited by 70
High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus
Ritsinger, V., Saleh, N., Lagerqvist, B., & Norhammar, A. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002328 · Cited by 67
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
ORIGIN Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc15-1676 · Cited by 66
Roussel, R., Steg, P. G., Mohammedi, K., Marre, M., & Potier, L. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13033 · Cited by 66
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P., Lange, M., Frandsen, K. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.004 · Cited by 66
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 72
Clinical utility of insulin and insulin analogs
Şanlioğlu, A. D., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2013) · Islets · doi:10.4161/isl.24590 · Cited by 65
Cukierman‐Yaffe, T., Bosch, J., Díaz, R., Dyal, L., Hâncu, N., Hildebrandt, P., Lanas, F. T., Lewis, B. S., Marre, M., Yale, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70062-2 · Cited by 64
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 63
Abdul-Ghani, M. A., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 64
Carrasco-Sánchez, F. J., Gómez-Huelgas, R., Formiga, F., Martel, A. C., Trullàs, J. C., Bettencourt, P., Arévalo‐Lorido, J. C., & Montero-Pérez-Barquero, M. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.03.015 · Cited by 64
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 63
50 years forward: mechanisms of hyperglycaemia-driven diabetic complications
Russell, N., & Cooper, M. E. (2015) · Diabetologia · doi:10.1007/s00125-015-3600-1 · Cited by 68
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 68
Evolution of Insulin Development: Focus on Key Parameters
Tibaldi, J. M. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0034-8 · Cited by 64
Gamble, J., Chibrikov, E., Twells, L., Midodzi, W. K., Young, S. W., MacDonald, D., & Majumdar, S. R. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30316-3 · Cited by 63
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Rotenstein, L. S., Ran, N. A., Shivers, J. P., Yarchoan, M. M., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.138 · Cited by 61
Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries
Siegal, D. M., Eikelboom, J. W., Lee, S. F., Rangarajan, S., Bosch, J., Zhu, J., & Yusuf, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa044 · Cited by 61
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Cefalu, W. T., Buse, J. B., Prato, S. D., Home, P., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 62
Comorbidities in Heart Failure
van der Wal, H. H., van Deursen, V. M., van der Meer, P., & Voors, A. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_27 · Cited by 63
Diabetes Mellitus and Colorectal Cancer Risk
Kallergi, A., Chambre, C., Duchemann, B., Fysekidis, M., & Bihan, H. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0274-5 · Cited by 61
Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes
Christou, M., Christou, P. A., Kyriakopoulos, C., Christou, G. A., & Tigas, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119357 · Cited by 65
Kelsey, M. M., Geffner, M. E., Guandalini, C., Pyle, L., Tamborlane, W. V., Zeitler, P. S., White, N. H., & for the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group (2015) · Pediatric Diabetes · doi:10.1111/pedi.12264 · Cited by 60
Shah, H., Gao, H., Morieri, M. L., SKUPIEN, J. K., Marvel, S. W., Paré, G., Mannino, G. C., Buranasupkajorn, P., Mendonça, C., Hastings, T., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0285 · Cited by 59
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 62
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Skra, J., Valensi, P. E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
